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Background: The pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) and steatohepatitis (NASH) is likely due to the interaction between a deranged metabolic milieu and local mediators of hepatic inflammation and fibrosis. Soluble (s)CD163 and the N-terminal neo-epitope of collagen type III (PRO-C3) have been recently proposed as non-invasive biomarkers of fibrogenesis in different chronic liver diseases. We aimed to assess the ability of sCD163 and PRO-C3, compared to liver stiffness (LS), for the detection of severe fibrosis in a well characterized cohort of NAFLD patients.

Methods: Circulating sCD163 and PRO-C3 were measured in a cohort of 219 biopsy-proven NAFLD patients (male, n=155 [71%]; type 2 diabetes, n=72 [33%]) and compared to LS by Fibroscan. Histology was scored according to Kleiner. Both sCD163 and PRO-C3 were measured by enzyme-linked immunosorbent assay. 

Results: Circulating sCD163, PRO-C3 levels and LS measurements showed a stepwise increase according to the degree of hepatic fibrosis (ANOVA all p<0.0001). Both sCD163 and PRO-C3 levels increased according to lobular inflammation (ANOVA p=0.042 and p=0.009, respectively), while only sCD163 increased according to ballooning degeneration (ANOVA p=0.001) and to the degree of hepatic steatosis (ANOVA p=0.007). A LS measurement higher than 9.6 kPa was able to predict severe fibrosis (F≥3) with an area under the receiveroperating curve (AUC) of 0.82 (Se 64%, Sp 76%, PPV 67%, NPV 84%). Concerning serum biomarkers, a sCD163 value higher than 580 ng/mL predicted F≥3 with an AUC of 0.78 (sensitivity [Se] 76%, specificity [Sp] 70%, positive predictive value [PPV] 52%, negative predictive value [NPV] 87%), while a PRO-C3 value higher than 12.1 ng/mL predicted F≥3 with an AUC of 0.72 (Se 59%, Sp 78%, PPV 54%, NPV 82%). By direct comparison, the diagnostic performance of LS in identifying severe fibrosis was significantly superior to PRO-C3 (dAUC=0.103, p=0.024) but not to sCD163 (dAUC=0.047, p=0.288).

Conclusion: Circulating sCD163 and PRO-C3 correlate with morphological features of NAFLD suggesting their involvement in the onset and progression of the disease. In particular, sCD163 may be a valid alternative tool to LS for the identification of severe fibrosis.
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